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Background: Although myelin is composed of mostly lipids, the pathological role
of myelin lipids in demyelinating diseases remains elusive. The principal lipid of the
myelin sheath is β-galactosylceramide (β-Galcer). Its α-anomer (α-Galcer) has been
demonstrated to be antigenically presented by macrophages via CD1d, a MHC class
I-like molecule. Myelin, which is mostly composed of β-Galcer, has been long considered
as an immunologically-inert neuron insulator, because the antigen-binding cleft of CD1d
is highly α-form-restricted.
Results: Here, we report that CD1d-mediated antigenic presentation of myelin-derived
galactosylceramide (Mye-GalCer) by macrophages contributed significantly to the
progression of experimental autoimmune encephalomyelitis (EAE). Surprisingly, this
presentation was recognizable by α-Galcer:CD1d-specific antibody (clone L363), but
incapable of triggering expansion of iNKT cells and production of iNKT signature
cytokines (IFNγ and IL-4). Likewise, a synthesized analog of Mye-Galcer, fluorinated
α-C-GalCer (AA2), while being efficiently presented via CD1d on macrophages, failed
to stimulate production of IFNγ and IL-4. However, AA2 significantly exacerbated
EAE progression. Further analyses revealed that the antigenic presentations of both
Mye-GalCer and its analog (AA2) in α-form via CD1d promoted IL-17 production
from T cells, leading to elevated levels of IL-17 in EAE spinal cords and sera.
The IL-17 neutralizing antibody significantly reduced the severity of EAE symptoms
in AA2-treated mice. Furthermore, D-sphingosine, a lipid possessing the same
hydrophobic base as ceramide but without a carbohydrate residue, efficiently blocked
this glycolipid antigen presentation both in vitro and in spinal cords of EAE
mice, and significantly decreased IL-17 and ameliorated the pathological symptoms.
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Conclusion: Our findings reveal a novel pathway from the presentation of Mye-GalCer
to IL-17 production, and highlight the promising therapeutic potential of D-sphingosine
for the human disorder of multiple sclerosis.
Keywords: endogenous myelin-derived galcer, antigen presentation, IL-17, EAE progression, D-sphingosine

INTRODUCTION

cytokines (e.g., IL-4 and IL-10) are elevated during disease
remission (12). Interestingly, activated NKT cells are capable of
producing both pro- and anti-inflammatory cytokines described
above (13). Indeed, contradictory effects of iNKT cells have
also been reported with a consensus that timing, administration
routes and extent of iNKT activation all determine its role,
protective or potentiating, in EAE (2, 14, 15). Therefore, a more
well-defined protective mechanism is needed for developing
therapeutic strategies for MS patients.
Variations in glycolipid structures impact on their interaction
with CD1d and NKT cells, and in turn on cytokine production
of NKT cells (16). Herein, we identified induction of IL-17 by
myelin-derived GalCer (Mye-Galcer). Briefly, endogenous MyeGalcer was found presented on myelin-laden macrophages. This
antigenic presentation of glycolipid was repeatedly recognized
by antibody L363, which is highly specific to the α-Galcer:CD1d
complex (7). To dissect the role of Mye-GalCer from other
components in myelin, we designed and synthesized an αgalactosyl lipid that resembles the Mye-GalCer in terms of its
antigenic presentation and downstream cytokine production.
Both Mye-Galcer and its synthetic analog induced IL-17
production. We also observed that D-sphingosine, a myelin
lipid without a carbohydrate residue, efficiently blocks the
presentation of Mye-GlyCer. MOG-induced EAE mice treated
with D-sphingosine exhibit much milder disease severity
and significantly improved survival rates. Our study shed a
considerable light on the therapeutic potentials of D-sphingosine
for MS patients.

Experimental autoimmune encephalomyelitis (EAE) is an
established mouse model that shares clinical and pathological
features of human multiple sclerosis (MS), an inflammatory
demyelinating disease of the central nervous system (CNS).
Various myelin-based proteins, such as myelin basic protein,
proteolipid protein, and myelin oligodendroglial glycoprotein
(MOG), have been proposed as the origin to the encephalitogenic
peptides presented to T cells via the MHC complexes, and
have been one of the foci of the studies in the field. However,
the immunological role of the principal lipid of myelin sheath,
galactosylceramide (GalCer), in EAE is not clear. Both protective
and aggravating effects of GalCer and its analogs have been
reported (1–3).
Glycolipid antigen presentation via CD1 has been shown to
activate CD1-restricted T cells (4). The CD1 molecule structurally
mimics MHC class I with a highly similar tertiary fold. However,
the antigen-binding cleft of CD1 is specific for lipids. Crystal
structure analyses of human and mouse CD1d (a CD1 subtype)
and α-galactosylceramide (α-GalCer, a glycolipid in a derivative
of a glycolipid from the marine sponge Agelas mauritianus)
have revealed that the sphingosine and the longer alkyl chain of
the ligand fit into two deep hydrophobic pockets, whereas the
galactose forms hydrogen-bonds with the outer portion of CD1d.
Such an orientation of amphipathic lipids allows hydrophilic
carbohydrate residues of the lipid to interact with the TCR for
activating immune responses (5).
Ceramides linked to β-galactose, rather than α-galactose, are
widely occurring in mammalian nervous tissues (e.g., myelin).
It was believed that α-GalCer was absent, because only one
UDP-galactose:ceramide β1→4 galactosyl transferase was found
in mammalian genomes (6). However, recent studies using αGalcer: CD1d specific antibody L363 detected a trace amount
(0.02%) of α-Galcer in mammalian species as an immune
agonist to invariant NKT cells (iNKT) (7–9). Additionally.
It has still been long ignored that anomerization (β- ↔ αanomer conversion) could occur in acidic condition, such as
in lysosome and late endosome of macrophages. Therefore,
positive detection of mammalian cells by α-GalCer:CD1d specific
antibody L363 (7–9) is possible, and suggests two possibilities:
(1) selective presentation of trace amount of α-GalCer or
(2) loading of anomerized β → α-GalCer onto CD1d in
lysosome/late endosome.
Imbalanced cytokine milieu also plays an important role
in initiation and perpetuation of the autoimmune pathology.
Increased production of pro-inflammatory cytokines (e.g.,
TNFα, IFNγ, and IL-17) occurs in cerebrospinal fluids, blood
mononuclear cells and brain lesions in MS patients during
an exacerbation phase (10, 11); whereas immune-suppressing
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MATERIALS AND METHODS
Mice
WT C57BL/6 mice were purchased from the Jackson Laboratories
(Bar Harbor, ME, USA). All mice were maintained in a pathogenfree facility. All animal protocols are in compliance with the
Guide for the Care and Use of Laboratory Animals (National
Institutes of Health) and proved by the Research Animal
Resource Center at Weill Cornell Medicine.

EAE Induction and Clinical Scoring
Female C57BL/6 mice (12 weeks of age or elder) were
immunized subcutaneously with 200 µg/mouse MOG35−55
peptide (Alpha Diagnostic Intl. Inc) emulsified in a 1:1 ratio
with complete Freund’s adjuvant (CFA, 2 mg/ml heat-inactivated
mycobacterium tuberculosis). Two doses of 200 ng pertussis
toxin were injected intraperitoneally on Day 1 (immunization
day) and Day 3. Severity of disease symptoms were scored from
0 to 5 in an increasing order of severity: 0, normal; 1, limp
tail or hind limb weakness; 2, limp tail and limb weakness or
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anti-αGalcer:CD1d (eBioscience, L363), CD86 (BD Bioscience,
GL1), TCRαβ (eBioscience,IP26), F4/80 (eBioscience, BM8),
IL17-A (Biolegend,TC11-18H10.1), NK1.1 (Biolegend, PK136),
and CD3 (Biolegend, 17A2). Cells were blocked with antiCD16/32 antibody (Biolegend) for 15 min before incubation
with fluorescently labeled antibodies at a concentration of
2 µg/ml for 45 min on ice. Stained cells were washed once
with FACS buffer and analyzed by FACSan (Becton Dickinson).
For internal staining, cells stained with surface makers were
fixed in 2% PFA Fixation buffer (eBioscience) at 4◦ C overnight,
followed by 3 washes with permeabilization buffer (R&D)
and incubation with permeabilization buffer for 20 min on
ice before staining with internal antibody. Stained cells were
washed once with permeabilization buffer and suspended in PBS
for analysis. Flow cytometry data were processed with FlowJo
software (Tree Star, inc.,).

weakness of 2 or more limbs; 3, severe limb weakness or single
limb paralysis; 4, paralysis of 2 limbs; 5, moribund or death. For
evaluating the exacerbating effects of AA2 in EAE progression,
the 2nd dose of PTX was waived for both control and AA2treated EAE mice.

Glycolipid
α-C-GalCer was prepared as previously described (17). The
new synthetic glycolipid AA2 was synthesized from a known
precursor following protecting group and amidation procedures
as described previously (18). Galcer purified from bovine spinal
cord and D-sphingosine were purchased from Matreya LLC and
Sigma-Aldrich respectively.

Mouse Treatment
Glycolipid AA2 and D-sphingosine were initially dissolved in
DMSO, followed by dilution with PBS and brief sonication.
After EAE induction, mice were injected i.p. every other day
with 10 µg AA2/mouse or with vehicle. Daily injection of Dspingosine via i.p. or i.v. started on day 3 after EAE induction.
Anti-IL-17 neutralizing antibody (100 µg/mouse, Biolegend) or
its isotype control (Rat IgG1) was given at Day 3, 5, 7, 9,
and 11 after EAE induction. All EAE mice were euthanized
on day 20–25. Spinal cords and brains were fixed by 4%
paraformaldehyde (PFA) for immunohistochemistry (IHC) and
immunofluorescence staining.

ELISA
Cell supernatant and mice serum were collected and stored
at −80◦ C until analysis. Spinal cords were excised and
homogenized via sonication with PBS supplemented with
protease inhibitor cocktail (Roche). Spinal homogenates were
centrifuged, and supernatants were collected and stored at
−80◦ C until analysis. IFNγ, IL-4, and IL-17A were measured
with ELISA kit purchased from eBioscience. The experiments
were performed according to the manufacturer’s instruction.
Briefly, the plates were coated with capture antibody at 4◦ C
overnight. The coated plate were blocked with assay diluent for
1 h at room temperature (RT). Samples were added to the plate
and incubated at RT for 2 h. Avidin-HRP and TMB substrate
were employed for detection of the cytokine signal of interest.
After the reactions were stopped with stop solution, the plates
were read for 450 nm values with subtraction of 570 nm values
within 30 min.

Cells Culture and in vitro Treatment
In vitro macrophages culture: Bone marrow aspirates of C57BL/6
mice were cultured in DMEM supplied with 10% FBS, 2 mM
glutamine, penicillin and 20% L929 cells supernatant for 6–7
days until mature mouse primary macrophages were formed.
The macrophages were treated with myelin debris or synthetic
glycolipids for 12, 24, and 48 h before examination of their
molecular traits. Myelin debris were prepared as described
previously (19). Untouched T cells-enriched splenetic cells were
acquired by depleting whole spleen single cell suspension of
B cells via B220 microbeads (Myltenyi Biotec) through LD
columns (Myltenyi Biotec) according to the manufacturer’s
manual. T cell percentage (85–92%) and viability (≥95%) were
verified by flow cytometric analysis. The T cells enriched splenetic
cells were added to macrophage layer to form the macrophageT cell co-culture system. After 2–3 h initial co-culture, myelin
debris, glycolipids, or D-sphingosine were further added to the
co-culture system.

In vitro Immunofluorescence Staining
Mature macrophages were immobilized on coverslips and treated
with myelin debris for various periods of time as indicated. At
the end of treatment, cells were washed with PBS, followed by
fixation and permeabilization with 4% PFA and 0.2% Triton
X100, respectively. The macrophages were further blocked
(PBS containing 5% FBS) and stained with aGalcer:CD1d
(eBioscience, L363) and adipored (Lonza) overnight at 4◦ C. After
counterstaining with 2.5 µg/ml DAPI (Invitrotgen) for 5 min at
RT, cells were mounted and subject to imaging with an inverted
fluorescence microscope (OLYMPUS).

Capture Antibody-Coated Beads
(CABs) Assays

Pathology of EAE Mice
Specimens (spinal cords and brains) were embedded in
low-melting-point paraffin wax and cut into 7 µm sections.
Sections stained with haematoxylin and eosin (H&E)
were microscopically examined for general histopathology
assessment. The immunostaining of iba1, IL-17A, and αGalCer were performed using a standard immunofluorescence
protocol. Briefly, formalin-fixed paraffin-embedded sections
were dewaxed and rehydrated in xylene, 100% ethanol, 95%
ethanol, 70% ethanol, 50% ethanol, and PBS sequentially.

Briefly, mouse IL-17A capture antibody-coated beads were added
to supernatants according to instructions of the manufacturer
(BD Bioscience). After incubation and 3 washes, the detection
antibody (anti-mouse IL-17A-PE) was added, followed by flowcytometric analysis.

Flow Cytometry Analysis
Antibodies employed in flow cytometric analysis were obtained
from various commercial sources: anti-CD1d (Biolegend, 1B1),
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macrophages to be loaded onto CD1d, we stained myelinladen macrophages with Periodic Acid-Shiff (PAS), which
specifically reacts with saccharides to give a magenta color,
at 24 h after initial feeding of myelin debris. As shown in
Figure 2A, a more eminent magenta color was exhibited by
myelin-laden macrophages when compared with non-treated
or adipose homogenate-fed macrophages. It suggested that
at least a portion of myelin lipids were intact as glycolipids
in phagosome/phagolysosome of macrophages. Macrophages
that ingested GalCer purified from bovine spinal cord showed
very similar flow cytomeric scatters (SSChigh /FSClow to
SSChigh /FSChigh ) and adipored-positive nature when compared
to myelin-laden macrophages (Figures 2B,C).
Two subsets of CD1d-restricted NKT cells have been
reported: namely invariant NKT (iNKT) cells which express
invariant TCRα chain (Vα14-Jα18) paired with a limited
number of TCRβ chains and noninvariant NKT cells which
use a diverse TCR repertoire (22). iNKT cells, but not
diverse NKT cells, are rapidly responsive to α-GalCer-loaded
CD1d-multimers. To clarify the lipid antigen presented
by myelin-laden macrophages, we first assessed myelinladen macrophages using an antibody (clone L363) that
specifically recognizes the α-GalCer:CD1d complex. We
employed the resting macrophages (SSClow /FSClow ) in same
culture plate as a control to observe the immunofluorescence
displayed by myelin-laden macrophages (SSChigh /FSClow to
SSChigh /FSChigh ). Surprisingly, immunofluorescence assays
revealed positive presentations of α-GalCer via CD1d on myelin
lipid-positive (adiporedhigh ) macrophages (Figure 2D, upper
panel). Macrophages fed with GalCer purified from bovine
spinal cords, which is mostly β-linked, showed α-GalCer
presentation with similar efficiencies when compared with whole
myelin-fed macrophages (Figure 2D, lower panel), suggesting
that this antigenic presentation was mainly contributed by
Mye-GalCer. Flow cytometric analysis confirmed that purified
GalCer and whole myelin stimulated macrophages to present
α-GalCer via CD1d to same extent (Figure 2E). However,
unlike the whole myelin, purified GalCer triggered cell death of
macrophages to some degree at later stage, and in turn different
cytokine milieu (data not shown), presumably due to the
cell death.

Acidic antigen retrieval and 5% sheep serum blocking
were performed before incubation with primary antibodies
overnight at 4◦ C. Sections were washed 3 times with
washing buffer (0.5% Tween 20 in PBS, pH 7.2), and
further subject to incubation with secondary antibody
conjugated with indicated fluorescence for 45 min at RT.
After counterstaining with Hoechst 33342, sections were
mounted and examined by laser scanning microscope
FV1000 (OLYMPUS).

Statistical Analysis
Student’s t-test was employed to calculate statistical significance
for difference between groups. A P < 0.05 was considered
statistically significant.

RESULTS
Molecular Features of Myelin-Laden
Macrophages
The myelin-targeting autoimmune responses rely on both innate
and adaptive components. Macrophages are professional
phagocytes that engulf and digest myelin debris. Upon
phagocytosis, macrophages serve as a bridge between innate
and adaptive immune responses (20). To characterize the
myelin-laden macrophages, bone marrow (BM)-derived
macrophages were fed with myelin debris and analyzed
for their molecular traits. A side scatter (SSC)high /forward
scatter (FSC)low population, indicating an increased inner
complexity of cells, was observed at 12 h after addition of
myelin debris. This population became SSChigh /FSChigh at
48 h, suggesting that the myelin-laden macrophages also
augmented in size (Figure 1A). Immobilized, myelin-laden
macrophages were stained with an orange-to-red lipid dye
(adipored), and then subject to microscopic observations.
The untreated macrophages appeared to be relatively small,
and exhibited low adipored fluorescence; whereas myelin-fed
macrophages were found complex, enlarged, and adipored-high
(Figure 1B). Since the only lipids in the culture were the purified
myelin lipids, the observation of lipid-positive macrophages
indicated that the SSChigh /FSChigh population represented
myelin-laden macrophages. We further explored the differences
between resting macrophages (SSClow /FSClow ) and myelinladen macrophages (from SSChigh /FSClow to SSChigh /FSChigh )
(Figure 1C). The latter showed significant up-regulation of
CD1d in comparison to the resting macrophages (Figure 1D).
A time-dependent gradual enhancement of the co-stimulatory
molecule CD86 on the cell surface (Figure 1E) further
suggested that myelin-laden macrophages are poised to activate
immune responses.

Mye-GalCer Presentation-Restricted
Cytokine Release
Both natural and synthetic α-GalCer are ligands for TCRs of
iNKT cells (23, 24). Upon activation, iNKT cells proliferate
and produce pro-inflammatory Th1 and anti-inflammatory Th2
cytokines. We therefore employed a co-culture system including
myelin-laden macrophages and splenetic T cells to examine IFNγ
and IL-4, the signature cytokines of iNKT cells (25, 26). To
our surprise, myelin-laden macrophages, while presenting MyeGalCer in α-form, stimulated neither expansion/proliferation of
NK1.1+ /TCRαβ+ cells (23) nor production of IFNγ and IL4, in sharp contrast to synthetic α-C-GalCer in the co-culture
system (Figures 3A,B).
Myelin is a complex coating that protects neuron fibers. In
order to dissect the role of Mye-GalCer from other myelin
components, studies with purified Mye-GalCer were desired.

Antigenic Presentation of Endogenous
Mye-GalCer via CD1d on Myelin-Laden
Macrophages
The discovery that both lipid and glycolipid antigens could be
recognized by T cells has greatly broadened our knowledge of
antigen repertoire (21). To determine whether the galactose
moiety were remained on myelin lipids long enough inside
Frontiers in Immunology | www.frontiersin.org

4

March 2019 | Volume 10 | Article 404

Ban et al.

Lipid Antigen Presentation Regulates EAE

FIGURE 1 | Characterization of myelin-laden macrophages. (A) Flow cytometric analysis of resting (reMϕ) vs. myelin-laden macrophages (mylMϕ) for side- and
forward-scatters at indicated time points after myelin internalization. (B) Fluorescent microscopy of resting (reMϕ) vs. myelin-laden macrophages (mylMϕ) 48 h postmyelin-internalization (lipid: red; nucleus: blue; BF: Bright Field; amplification: 20x). (C) Gating strategies for resting and myelin-laden macrophages. (D,E) Flow
cytometric analysis of CD1d expression (D) and CD86 expression (E) by resting vs. myelin-laden macrophages.

responses (16), we designed a series of modified α-C-GalCers
and screened them in both co-culture system and C57/B6 mice.
We discovered that α-C-Fluoro-GalCer (AA2) mimicked MyeGalcer. As shown in Figure 3C, AA2 was efficiently presented
via CD1d and readily detectable by antibody L363, while
neither proliferation of NK1.1+ / TCRαβ+ cells (Figure S1)

However, the unexpected cell death elicited by the purified
bovine GalCer urged us to seek for a monomer mimicking
Mye-GalCer in terms of all its subsequent bioactivities. Given
that a subtle structural alteration of glycolipid ligand could
largely affect the affinity of the glycolipid-CD1d complex to
TCR of NKT cells, and in turn markedly different cytokine
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FIGURE 2 | Antigenic presentation of Mye-Galcer by myelin-laden macrophages. (A) Periodic Acid-Shiff reactions (magenta) of resting macrophages, myelin-laden
macrophages and adipose-treated macrophages. (B) Gating strategies for resting and Galcer-laden macrophages. (C) Microscopy of Galcer-laden macrophages
stained with a lipid dye (Adipored). Control: resting macrophages, indicated by white arrow head; Galcer-laden macrophages indicated by yellow head. BF: Bright
Field (D) Fluorescent microscopy of antigenic presentation of Galcer on myelin- and Galcer-laden macrophages stained with anti-CD1d:Galcer (L363, green), adipored
(red), and Dapi (blue). Resting macrophages and myelin-laden macrophages were indicated by white and yellow arrow head, respectively. (E) Flow cytometric analysis
of CD1d up-regulation by myelin- and Galcer-laden macrophages.
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FIGURE 3 | Elevated IL-17 expression following antigenic presentation of Mye-Galcer. (A) Gating strategies for NK1.1+ /TCRαβ+ cells (left) and proliferation of
NK1.1+ /TCRαβ+ cells when co-cultured with myelin- or α-C-GC laden macrophages (right). Y-axis represents the percentage of EDU positive cells; X-axis presents
time (day) post-EDU addition. (B) IFNg and IL-4 expression in the co-culture system described in (A). (C) Chemical structures of β-GalCer and α-C-Fluoro-GalCer
(AA2) and antigenic Galcer presentation by macrophages treated with myelin debris or AA2 (CD1d::Galcer complex was detected by clone L363). (D) IFNγ and IL-4
expression in the co-culture system comprising splenetic T cells and α-C-GC- and AA2- treated macrophages. (E) Quantification of IFNγ, IL-4, and IL-17A in mouse
sera collected from mice treated with α-C-GC, AA2, or the combination of α-C-GC and AA2 at indicated time points. (F) Disease progression of untreated and
AA2-treated EAE mice. For evaluating the exacerbating effects of AA2, induction of EAE by MOG35−55 without PTX booster was employed. (G) Left: IL-17A
expression in the co-culture systems comprising splenetic T cells and macrophages treated with AA2, myelin or α-C-GC; right: quantification of IL-17A in mouse sera
collected from healthy mice treated with or without AA2, healthy mice adoptively transferred with myelin-laden macrophages, EAE mice and EAE mice treated AA2.
IL-4 and IFNγ in same experiment setting were shown as controls. **p < 0.05, and ***p < 0.01.

of IL-17A was dramatically elevated in AA2-treated healthy
mice (Figure 3E right). We further employed the co-culture
system including AA2-pulsed macrophages and splenetic T
cells. Co-culture systems with myelin-laden- or α-C-Galcerpulsed macrophages as previously described served as controls.
Not surprisingly, the myelin-mimicking AA2 and myelin, but
not α-C-Galcer, increased production of IL-17A in co-culture
system (Figure 3G, left). We next tested sera collected from
EAE mice treated with or without AA2. Sera collected from
healthy mice received PBS, AA2, and adoptive-transferred,
myelin-laden-macrophages served as controls. Consistently,
as shown in Figure 3G (left), AA2 further elevated IL17A levels, but not IL-4 and IFNg , in sera of EAE mice
(Figure 3G, right).

nor cytokine production (IFNγ & IL-4) was significantly
stimulated in vivo and in vitro (Figures 3D,E, left and middle).
Empowered with this Mye-Galcer-mimicking lipid monomer,
we were able to study an IFNγ & IL-4-independent mechanism
subsequent to glycolipid presentation. We observed that AA2
exacerbated the symptoms of MOG33−55 -initiated EAE, as
evidenced by earlier onset of disease and significantly higher
EAE scores (Figure 3F). This interesting observation prompted
us to ask which cytokine(s) other than IFNγ and IL-4 was
responsive to AA2 challenge. The inflammatory cytokine IL17 driven by both RORγt and T-bet has been shown to
be crucial to autoimmune demyelinating diseases of CNS
(27, 28). We, therefore, examined IL-17A production in
response to AA2 challenge. As we expected, the serum level
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Deprivation of Mye-Galcer Presentation
by D-Sphingosine

Finally, to confirm that AA2-induced exacerbation of EAE
symptoms was IL-17-mediated, AA2-treated EAE mice were
co-treated with either IL-17A neutralizing antibody or its
isotype control. As expected, IL-17A neutralizing antibody
significantly ameliorated the EAE symptoms exacerbated by AA2
(Figures 4A,B and Videos S1, S2).

Our findings that both myelin-originated and AA2-simulated
α-GalCer presentation associated with the elevated IL-17
production raised the question whether abrogation of this
glycolipid antigen presentation could impede IL-17 production.

FIGURE 4 | Role of IL-17 in AA2-exacerbated EAE. (A) Mice were induced with EAE and treated with IgG, IL-17 neutralizing antibody (anti-IL-17), AA2 combined with
IgG, or AA2 combined with anti-IL-17 (n = 6 mice/group). The course of disease was monitored and clinical scores were determined. (B) Survival curves of EAE mice
treated with AA2 combined with IgG or AA2 combined with anti-IL-17. There was no death in groups treated with IgG alone or anti-IL17 alone. For evaluating the
exacerbating effects of AA2, induction of EAE by MOG35−55 without PTX booster was employed. ***p < 0.01.

FIGURE 5 | Deprivation of antigenic presentation of Mye-Galcer by D-Sphingosine. (A) Chemical sketch of D-Sphingosine. (B) Flow cytometric analysis of
Mye-Galcer presentation by macrophages treated with D-Sphingosine, myelin, or the combination of D-Sphingosine and myelin. Macrophages were cultured in 10%
cs-FBS media during the treatments. (C) Flow cytometric analysis of CD1d up-regulation by macrophages described in 4 (B). (D,E) IL-17A production in myelin-laden
macrophages/T cell co-culture system treated with or without D-sphingosine measured by CAB assays coupled with Flow cytometric analysis (D) and ELISA
(E). CD1d neutralizing antibody was employed as in myelin-laden macrophages/T cell co-culture system as an additional control to confirm that the increase of IL-17
is due to CD1d-mediated antigen presentation (E right). **p < 0.05, and ***p < 0.01. Data are representative of 2–3 independent experiments.
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FIGURE 6 | Therapeutic effects of D-Sphingosine on EAE. (A) Clinical scores and disease onsets of EAE mice treated with or without D-Sphingosine (i.p or i.v.).
(B) H&E staining of spinal cords from healthy and the EAE mice described in 5 (A). Pia matter indicated by a black arrow. Amplification 10x. (C) Fluorescent
microscopy of the distribution of F4/80+ microglia/macrophages below lumbar segment L1 of spinal cords from healthy and the EAE mice described in (A). (D) Flow
cytometric analyses of Mye-Galcer presentation by microglia/macrophages and IL-17A production by T cells in spinal cords from EAE mice treated with or without
D-Sphingosine (i.p.). (E,F) Fluorescent microscopy of CD1d:α-GalCer (red), microglia/macrophage clusters (iba1, magenta) and IL-17-producing cells (Green) in spinal
cords from healthy and the MOG35−55 -induced EAE mice treated with or without D-Sphingosine (i.p.) (n = 5/group). ***p < 0.01. Data are representative of 3
independent experiments.
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Substantial Amelioration of EAE Severity
by D-Sphingosine Treatment

In this context, we next explored myelin lipids. The primary
lipid of myelin is β-GalCer with a monogalactose glycosidically
linked to the C-1 hydroxyl group of ceramide. Ceramide could be
further broken down to sphingosine via ceramidase. Sphingosine
(skeptical presentation shown in Figure 5A) and sphingosine1-phosphate (S1P) are interchangeable via phosphorylation and
dephosphorylation mediated, respectively, by sphingosine kinase
type 1/2 and S1P phosphatase/S1P lysase (29, 30). However,
S1P could not be efficiently formed in medium supplemented
with 10% charcoal-stripped serum (cs-FBS) (31). We discovered
that in medium supplemented with 10% cs-FBS, D-sphingosine
(insoluble fine particles), but not S1P, efficiently blocked MyeGalCer presentation on myelin-laden macrophages (Figure 5B).
Treatment with D-sphingosine did not abolish the upregualtion
of CD1d of myelin-laden macrophages, because when being
stained with antibody that only recognizes CD1d protein,
no difference was observed between D-sphingosine-treated
and untreated myelin-laden macrophages (Figure 5C). These
observations suggested that D-sphingosine only occupied the
antigen-binding cleft without affecting CD1d expression.
To determine whether IL-17, the key cytokine associated with
Mye-GalCer presentation, was also inhibited by D-sphingosine,
we employed capture antibody-coated beads (CABs) (Figure 5D)
and ELISA (Figure 5E) to test the IL-17A in the co-culture of
myelin-laden macrophages and T cells pulsed with or without
D-sphingosine. CD1d-neutralizing antibody served as a negative
control. As we expected, myelin-laden macrophages failed to
elevate the level of IL-17A when pretreated with D-sphingosine.

We hypothesized that blockade of Mye-GalCer presentation
could lead to a significant decrease in IL-17-mediated
immune responses and thus amelioration of EAE. To test
this hypothesis, MOG35−55 -immunized mice were treated with
D-sphingosine (insoluble fine particles) intraperitoneally (i.p.)
or intravenously (i.v.).
Both i.p. and i.v. groups of mice receiving D-Sphingosine
demonstrated significantly lowered clinical scores and delayed
onsets compared to control EAE mice. The mean scores of
i.v. group were further lower by a grade of 0.61 ± 0.11 than
i.p. group (Figure 6A, Supplementary Table 1, Videos S3, S4).
Histopathologically, control mice with EAE displayed extensive
necrotizing lesions of pia matter and subpial inflammatory
infiltrates; in contrast, D-Sphingosine-treated mice at the
same time points showed dramatically more restricted pia
matter necrosis and striking reductions of subpial inflammation
[hematoxylin & eosin (H&E)-stained spinal cord sections
shown in Figure 6B]. Consistently, animals in i.v. group
demonstrated even less impairment of spinal cord than those
in i.p. group. It has been well-accepted that the demyelinating
lesions are characterized and defined by both residing and
infiltrating macrophages (19, 32–34). We next employed the
microglia/macrophage marker F4/80 to examine the spinal cord
portion below lumbar segment L1. As shown in Figure 6C,
F4/80+ cells significantly concentrated throughout lumbar
to sacral segments in control EAE mice; whereas such a

FIGURE 7 | Phased cytokine production in EAE mice. Quantification of IL-17 and IFNg in sera and spinal cord homogenates collected from EAE mice treated with or
without D-Sphingosine (i.p. or i.v.) at the onset and the peak of disease (n = 6/group). **p < 0.05, and ***p < 0.01.
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macrophages after being exposed to myelin debris in vitro and
in vivo have also been reported (19, 41–44). While partially
consistent with anti-inflammatory role in regard to low IFNγ/IL4 ratio, our findings point to the possibility that after myelin
debris internalization, α-GalCer-presenting macrophages lead
to the increased production of IL-17. This observation was
corroborated by the previous reports that in inflamed spinal
cord, foamy macrophages strongly express IL-6, the cytokine
essential for encephalitogenic IL-17+ cell differentiation (28,
32, 45). We demonstrated for the first time that the myelinladen macrophage serves as a pro-inflammatory player in a noncanonical way in EAE spinal cords, and shed a considerable light
for reconciling the detrimental role of myelin-laden macrophages
with its incapability of eliciting IFNγ. Our data showed that
NK1.1+ iNKT were not reactive when co-cultured with myelinladen macrophages, further investigation are needed to confirm
that the NKT-17 cells are the downstream effectors responding to
the myelin-derived, α-GalCer presentation.
Both Th1 and Th-17 cells have been proposed to be involved
in pathogenesis of EAE (27). Observations that IFNγ-deficient
mice are susceptible to EAE (46), and IL-17-deficient mice still
developed EAE only with less severe symptoms (47, 48) indicate
that induction and progression of EAE are dependent on an
imbalanced cytokine network, not a single pro-inflammatory
mediator. Our investigations on supernatants of spinal cord
homogenates and sera collected from EAE mice showed that
IL-17A, not IFNγ, is one of the predominant cytokines at the
disease onset stage locally (spinal cord) and systematically
(serum); quenching this early expression of IL-17A by Dsphingosine decreased IFNγ in spinal cord at the peak of
disease (Figure 7). IL-1β and TNFα also declined to various
degrees in D-sphingosine-treated spinal cords (data not shown).
Together, our findings suggest Mye-GalCer presentationassociated IL-17A expression at the onset stage of EAE plays
an important role in building up the inflammatory network
at disease climax, and highlight the therapeutic potentials
of D-sphingosine.
Intravenous administration of D-sphingosine could involve
the effects of both sphingosine and S1P resulted from
phosphorylation of sphingosine in blood stream, since the
signaling axis of ApoM-S1P-S1P receptor 1 significantly restrains
lymphopoiesis, and in turn the adaptive immune responses
in CNS (49). Intraperitoneal administration of insoluble fine
particles (D-sphingosine resuspended in PBS), in contrast, are
known to be absorbed to lymphatic circulation (50, 51) where
most of D-sphingosine are likely to stay in an unphosphorylated
form before they are engulfed by phagocytes, due to the much
lower level of ApoM in lymph than in blood (49, 52). These
explain why D-sphingosine i.v. achieved better clinical cores than
i.p. group while having comparable efficiency of abrogating the
lipid antigen presentation.

clustering of macrophages dissipated upon D-sphingosine
treatment regardless of the administration routes. Depletion of
hematogenous macrophages has been shown to promote myelin
preservation and neuron sprouting (35). Thus, our observations
of D-sphingosine-induced reduction of macrophages paralleled
with its therapeutic effects in EAE mice. More importantly, flow
cytometric analysis showed that the Mye-GalCer presentation by
macrophages in situ of EAE spinal cord was notably abrogated
by D-sphingosine treatment (Figure 6D, upper). In the same
experimental settings, the expression of cytokine IL-17 of
CD3+ population was investigated. A strong correlation between
myelin-originated Mye-GalCer presentation by macrophages
and production of IL-17A by CD3+ cells in spinal cords was
observed (Figure 6D, lower). We further discovered that IL17A+ T cells in control EAE and AA2-treated EAE spinal
cords were largely CD3+ /NK1.1− /CD4− /CD8+/− , suggesting
that the downstream effector T cells were not the canonical iNKT
cells (Figure S2).
We next set out to determine the micro-locations of the
lipid antigen and IL-17A via immunofluorescence analysis of
EAE spinal cords with or without D-sphingosine treatment.
As shown in Figure 6E (upper and middle panels), the spinal
cord from healthy mice was largely devoid of macrophages
clusters, which were identified by microglia/macrophagespecific protein, ionized calcium binding adapter molecule
1 [iba1, (36)]. Neither Mye-GalCer presentation (red) nor
IL-17A expression (green) was markedly evident in healthy
spinal cord. However, the spinal cord of control EAE mice
exhibited multiple macrophage plaques presenting α-GalCer.
IL-17A-producing cells were found partially co-localizing with
macrophage plaques. Direct conjugation of IL-17A-producing
cells to GalCer antigen was also observed (Figure 6F). In
contrast, D-sphingosine abrogated myelin-originated GalCer
presentation by macrophages, mitigated the macrophage plaques
and the accumulation of IL-17A-producing cells on or near the
macrophage plaques (Figure 6E, lower panel). Collectively, our
study demonstrated an axis from lipid antigen presentation to
IL-17 production.

DISCUSSION
CD1d-restricted NKT cells have been shown to possess
abilities to produce diverse cytokines, including IFNγ, IL-2,
IL-3, IL-4, IL-6, IL-10, IL-17, etc. Compared to other NKT
subsets, an unconventional CD4− /NK1.1− NKT cell population
appears to be primarily responsible for the production of IL17 (referred as NKT-17 hereafter) (13). Consistent with the
previous findings, we discovered that the IL-17-producing T
cells activated by endogenous mye-Galcer or AA2 are largely
CD3+ / CD4− /NK1.1− /CD8+/− (Figure S2). It is nevertheless
unclear precisely how the “on-switch” of NKT-17 is triggered in
the autoimmune disease settings. On the other hand, myelinphagocytosing macrophages (foamy macrophages) was viewed
as anti-inflammatory regulators with an important role of
clearing myelin debris as a prerequisite for remyelination (32,
37–40). Conversely, the pro-inflammatory characteristics of
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